Monitoring the efficacy of antimicrobial photodynamic therapy in a murine model of cutaneous leishmaniasis using L. major expressing GFP.
A murine model of cutaneous leishmaniasis with green fluorescent protein positive (GFP+) L. major enables the monitoring of parasitic load via measurements of GFP fluorescence intensity, allowing for a faster and more efficient way of monitoring the clinical outcome of photodynamic therapy (PDT). This model may provide new insights on the phototoxic aspects in PDT. Although PDT regimens may be somewhat different in humans, it is expected that the developed model will facilitate the optimization and clinical translation of PDT as a therapy for cutaneous leishmaniasis and the eventual development of topical PDT treatments for other granulomatous infections.
Latorre-Esteves
Elena
E
Wellman Centre for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA.
Akilov
Oleg E
OE
Rai
Prakash
P
Beverley
Stephen M
SM
Hasan
Tayyaba
T
D000818:Animals; D002138:Calibration; D004195:Disease Models, Animal; D004427:Ear Diseases / Q000188:drug therapy / Q000469:parasitology; D005260:Female; D005453:Fluorescence; D049452:Green Fluorescent Proteins; D018320:Leishmania major / Q000187:drug effects* / Q000378:metabolism; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D010640:Phenothiazines / Q000494:pharmacology / Q000627:therapeutic use*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015203:Reproducibility of Results; D014162:Transfection; D016896:Treatment Outcome
C525896:3,7-bis(N,N-dibutylamino)phenothiazinium bromide; D010640:Phenothiazines; D017319:Photosensitizing Agents; D049452:Green Fluorescent Proteins